University of Arizona Oncology Researcher Adds Third-Drug to Existing Biliary Tract Cancers

Jul 9, 2019 | Cancer, Investigator Content, Oncology, Shroff, Rachna Content, University of Arizona

Glass laboratory chemical test tubes with red liquid.Man wears p

Rachna Shroff is the chief of the section of gastrointestinal (GI) medical oncology at the UA Cancer Center. Shroff has been conducting research in improving the survival of patients with biliary tract cancers. Dr. Shroff recently discussed her research—involving the addition of a third drug, nab-paclitaxel, to the existing two drug treatment of gemcitabine and cisplatin for biliary tract cancers. She was interviewed by the University of Arizona Daily Wildcat. She is also profiled in TrialSite News’ Investigator Profile.

Dr. Shroff interest in medicine started back when she attended high school in Tucson, Arizona. With a physician mom and a biochemist dad at the University of Arizona (UA), she naturally ended up following in their footsteps professionally. After some initial cancer research, she developed a deep professional interest in oncology research. 

Dr. Shroff’s profile highlights reveal a busy professional. She is currently serving as the following:

  •         Associate Professor, Medicine (Clinical Scholar Track)
  •         Chief, Section of GI Medical Oncology, UA Cancer Center
  •         Leader, GI Disease-Oriented Team, UA Cancer Center
  •         Chair, Data Safety Monitoring Board, UA Cancer Center

Follow the link below for the Arizona Wildcat news interview.


Pin It on Pinterest